Acute Myeloid Leukemia

About
Mappings

NCI Thesaurus: Acute Myeloid Leukemia (coding:ncit:C3171)

OncoTree: Acute Myeloid Leukemia (coding:oncotree:AML)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
FDA (2) IDH2 p.R140Q Acute Myeloid Leukemia Enasidenib
FDA (2) IDH2 p.R140L Acute Myeloid Leukemia Enasidenib
FDA (2) IDH2 p.R140G Acute Myeloid Leukemia Enasidenib
FDA (2) IDH2 p.R140W Acute Myeloid Leukemia Enasidenib
FDA (2) IDH2 p.R172K Acute Myeloid Leukemia Enasidenib
FDA (2) IDH2 p.R172M Acute Myeloid Leukemia Enasidenib
FDA (2) IDH2 p.R172G Acute Myeloid Leukemia Enasidenib
FDA (2) IDH2 p.R172S Acute Myeloid Leukemia Enasidenib
FDA (2) IDH2 p.R172W Acute Myeloid Leukemia Enasidenib
EMA (1) FDA (2) FLT3-ITD Acute Myeloid Leukemia Gilteritinib
EMA (1) FDA (2) FLT3 p.D835Y Acute Myeloid Leukemia Gilteritinib
FDA (2) FLT3 p.D835A Acute Myeloid Leukemia Gilteritinib
FDA (2) FLT3 p.D835E Acute Myeloid Leukemia Gilteritinib
FDA (2) FLT3 p.D835H Acute Myeloid Leukemia Gilteritinib
FDA (2) FLT3 p.D835N Acute Myeloid Leukemia Gilteritinib
FDA (2) FLT3 p.D835S Acute Myeloid Leukemia Gilteritinib
FDA (2) FLT3 p.D835V Acute Myeloid Leukemia Gilteritinib
FDA (4) IDH1 p.R132C Acute Myeloid Leukemia Ivosidenib
FDA (4) IDH1 p.R132G Acute Myeloid Leukemia Ivosidenib
FDA (4) IDH1 p.R132H Acute Myeloid Leukemia Ivosidenib
FDA (4) IDH1 p.R132L Acute Myeloid Leukemia Ivosidenib
FDA (4) IDH1 p.R132S Acute Myeloid Leukemia Ivosidenib
EMA (1) FDA (2) IDH1 p.R132C Acute Myeloid Leukemia Azacitidine, Ivosidenib
EMA (1) FDA (2) IDH1 p.R132G Acute Myeloid Leukemia Azacitidine, Ivosidenib
EMA (1) FDA (2) IDH1 p.R132H Acute Myeloid Leukemia Azacitidine, Ivosidenib
EMA (1) FDA (2) IDH1 p.R132L Acute Myeloid Leukemia Azacitidine, Ivosidenib
EMA (1) FDA (2) IDH1 p.R132S Acute Myeloid Leukemia Azacitidine, Ivosidenib
EMA (1) FDA (2) FLT3-ITD Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (2) FLT3 p.D835Y Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (2) FLT3 p.D835A Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (2) FLT3 p.D835E Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (2) FLT3 p.D835H Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (2) FLT3 p.D835N Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (2) FLT3 p.D835S Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (2) FLT3 p.D835V Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (2) FLT3 p.I836del Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (2) CDK12 oncogenic variants Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (2) IDH1 p.R132C Acute Myeloid Leukemia Olutasidenib
FDA (2) IDH1 p.R132G Acute Myeloid Leukemia Olutasidenib
FDA (2) IDH1 p.R132H Acute Myeloid Leukemia Olutasidenib
FDA (2) IDH1 p.R132L Acute Myeloid Leukemia Olutasidenib
FDA (2) IDH1 p.R132S Acute Myeloid Leukemia Olutasidenib
FDA (2) t(KMT2A;v) Acute Myeloid Leukemia Revumenib
EMA (1) CD33 + Acute Myeloid Leukemia Cytarabine, Daunorubicin, Gemtuzumab ozogamicin
EMA (1) FDA (2) FLT3-ITD Acute Myeloid Leukemia Quizartinib
EMA (1) FDA (2) FLT3-ITD Acute Myeloid Leukemia Cytarabine, Daunorubicin, Quizartinib
EMA (1) FDA (2) FLT3-ITD Acute Myeloid Leukemia Cytarabine, Idarubicin, Quizartinib
FDA (2) NPM1 p.W288Cfs*12 Acute Myeloid Leukemia Ziftomenib
FDA (2) NPM1 p.W288Cfs*12 Acute Myeloid Leukemia Revumenib